Up a level |
Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian, Clark, Richard ORCID: 0000-0002-1261-3299 et al (show 1 more authors)
(2016)
Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial.
Haematologica: the hematology journal, 101 (6).
pp. 724-731.
Love, Sharon B, Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca et al (show 26 more authors)
(2022)
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Trials, 23 (1).
p. 757.
Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne T, Hemmaway, Claire, Greaves, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi et al (show 1 more authors)
(2021)
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
BRITISH JOURNAL OF HAEMATOLOGY, 194 (2).
pp. 298-308.